Abiopharma

🔍 SOLOMON DAVID M (Director)

Company: GOLDMAN SACHS GROUP INC (GS)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Acquired 34,017 shares of Common Stock, par value $0.01 per share (Direct)
  Date: 2026-04-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 159,544.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 18,812 shares of Common Stock, par value $0.01 per share at $937.81 per share (Direct)
  Date: 2026-04-28 | Code: F | equity_swap_involved: 0 | shares_owned_after: 140,732.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Holds 0 shares of Common Stock, par value $0.01 per share (Direct)
  Date: 2026-04-28 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 16,171.00 | Footnotes: F3
• Sold 34,017 shares of Performance-based Restricted Stock Units (Derivative)
  Date: 2026-04-28 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

Footnotes:

• F1: On April 28, 2026, shares of the Issuer's common stock underlying an award of Performance-based Restricted Stock Units ("PSUs") granted on January 26, 2023 in connection with 2022 year-end compensation were delivered to the Reporting Person without the payment of any consideration. These shares generally cannot be sold or transferred before January 2027.
• F2: Represents shares of the Issuer's common stock withheld to satisfy withholding obligations in connection with the delivery of the common stock underlying the PSUs described in footnote 1 above.
• F3: Held through a trust, the sole beneficiaries of which are immediate family members of the Reporting Person. The Reporting Person disclaims beneficial ownership of these shares.